Orhan Kucuksahin et al[23] used Secukinumab, an IL-17 inhibitor, to treat patients with both MS and AS and observed the alleviation of symptoms in both diseases, suggesting that the IL-17 pathway might play a role in the shared pathological processes of AS and MS. This evidence concerns the gene IL17A and myeloid sarcoma.